



**U.S. Department of
Health and Human Services**
Centers for Disease
Control and Prevention

Print Date: 5/24/24

Title: Evaluating Funded OD2A Partner Implementation and Impacts of Stop Overdose Campaigns

Project Id: 0900f3eb823164c0

Accession #: NCIPC-CB-2/23/24-164c0

Project Contact: Diakima Y Thomas

Organization: NCIPC/DOP/CB

Status: **Project In Progress**

Intended Use: **Project Determination**

Estimated Start Date: 07/01/2024

Estimated Completion Date: 09/30/2024

CDC/ATSDR HRPO/IRB Protocol #: n/a

OMB Control #: 0920-0879

Determinations

Determination	Justification	Completed	Entered By & Role
HSC: Does NOT Require HRPO Review	Not Research / Other 45 CFR 46.102(l) Quality Assurance / Improvement	3/15/24	Angel_Karen C. (idy6) CIO HSC
PRA:			

PRA Applies		3/15/24	Angel_Karen C. (idy6) OMB / PRA
ICRO: PRA Applies	OMB Approval date: 8/29/23 OMB Expiration date: 8/31/26	3/15/24	Zirger_Jeffrey (wtj5) ICRO Reviewer

Description & Funding

Description

Priority:	Standard
Date Needed:	04/01/2024
Priority Justification:	
CDC Priority Area for this Project:	Not selected
Determination Start Date:	02/23/24
Description:	To evaluate OD2A partner implementation of CDC"s Stop Overdose campaign materials and products.
IMS/CIO/Epi-Aid/Lab-Aid/Chemical Exposure Submission:	No
IMS Activation Name:	Not selected
Submitted through IMS Clearance Matrix:	Not selected
Primary Scientific Priority:	Not selected
Secondary Scientific Priority (s):	Not selected
Task Force Responsible:	Not selected
CIO Emergency Response Name:	Not selected
Epi-Aid Name:	Not selected
Lab-Aid Name:	Not selected
Assessment of Chemical Exposure Name:	Not selected
Goals/Purpose	1.Increase use of Stop Overdose campaign materials and products among OD2A partners; 2.Enhance Stop Overdose campaign materials and products, dissemination tactics, and support to optimize the use of campaign materials by OD2A partners.
Objective:	1.Assess how and to what extent CDC-funded OD2A partners have implemented Stop Overdose campaigns since their launch; 2. Assess the perceived effectiveness of Stop Overdose materials and products among OD2A partners for supporting their work; 3. Identify barriers, facilitators, and areas of need and support for OD2A partners using Stop Overdose campaigns to support their drug overdose prevention work.

Does your project measure health disparities among populations/groups experiencing social, economic, geographic, and/or environmental disadvantages?:

No

Does your project investigate underlying contributors to health inequities among populations /groups experiencing social, economic, geographic, and/or environmental disadvantages?:

No

Does your project propose, implement, or evaluate an action to move towards eliminating health inequities?:

No

Activities or Tasks:

New Collection of Information, Data, or Biospecimens

Target Populations to be Included/Represented:

Other - OD2A partners (adults 18>)

Tags/Keywords:

Program Evaluation

CDC's Role:

Activity originated and designed by CDC staff, or conducted at the specific request of CDC, or CDC staff will approve study design and data collection as a condition of any funding provided

Method Categories:

Survey

Methods:

Online survey to collect quantitative and some qualitative (open-ended) responses

Collection of Info, Data or Biospecimen:

Sample and recruitment. All current OD2A grantee organizations at the time of data collection will be invited to complete one survey. CDC will advise partners of the pending survey invitation, and the contractor will invite partners to participate through an email invitation. Partners will be instructed to designate one person to complete the survey on behalf of the organization. The invitation will include a unique link to the survey and may get input from other colleagues. Participants will receive two reminder emails after the initial invite. Survey instrument. The survey instrument will measure in six key domains to inform on the delivery of Stop Overdose campaigns. The survey will take up to 20 minutes to complete and include multiple choice and open-ended items. The research team will develop the survey, and CDC will approve the final instrument. The Fors Marsh survey team will program, test, and create a link for the survey. The survey team will collect and clean the data for analysis.

Expected Use of Findings/Results and their impact:

The Fors Marsh will provide CDC with a report within 4 weeks of final data collection. They will provide a written final report in Microsoft Word with an executive summary, key takeaways, methods, and a summary of evaluation results and findings for each data collection effort. They will submit all de-identified raw and finalized data. CDC will have the opportunity to provide one round of feedback, and the research team will address feedback and provide a final report.

Could Individuals potentially be identified based on Information Collected?

No

Funding

Funding Type	Funding Title	Funding #	Original Budget Yr	# Years Award	Budget Amount
--------------	---------------	-----------	--------------------	---------------	---------------

CDC Contract	Drug Overdose Campaign Research	75D30121F11264	2021	3	4499843.35
--------------	---------------------------------	----------------	------	---	------------

HSC Review

HSC Attributes

Quality Assurance / Improvement Yes

Regulation and Policy

Do you anticipate this project will need IRB review by the CDC IRB, NIOSH IRB, or through reliance on an external IRB? No

Estimated number of study participants

Population - Children

Protocol Page #:

Population - Minors

Protocol Page #:

Population - Prisoners

Protocol Page #:

Population - Pregnant Women

Protocol Page #:

Population - Emancipated Minors

Protocol Page #:

Suggested level of risk to subjects

Do you anticipate this project will be exempt research or non-exempt research

Requested consent process wavers

Informed consent for adults No Selection

Children capable of providing assent No Selection

Parental permission	No Selection
Alteration of authorization under HIPAA Privacy Rule	No Selection

Requested Waivers of Documentation of Informed Consent

Informed consent for adults	No Selection
Children capable of providing assent	No Selection
Parental permission	No Selection

Consent process shown in an understandable language

Reading level has been estimated	No Selection
Comprehension tool is provided	No Selection
Short form is provided	No Selection
Translation planned or performed	No Selection
Certified translation / translator	No Selection
Translation and back-translation to/from target language(s)	No Selection
Other method	No Selection

Clinical Trial

Involves human participants	No Selection
Assigned to an intervention	No Selection
Evaluate the effect of the intervention	No Selection
Evaluation of a health related biomedical or behavioral outcome	No Selection
Registerable clinical trial	No Selection

Other Considerations

Exception is requested to PHS informing those bested about HIV serostatus	No Selection
Human genetic testing is planned now or in the future	No Selection

Involves long-term storage of identifiable biological specimens No Selection

Involves a drug, biologic, or device No Selection

Conducted under an Investigational New Drug exemption or Investigational Device Exemption No Selection

Institutions & Staff

Institutions

Will you be working with an outside Organization or Institution? Yes

Institution	FWA #	FWA Exp Date	Funding	Funding Restriction Amount
Fors Marsh Group LLC	FWA00011194	12/05/24	Drug Overdose Campaign Research - 75D30121F11264	

Institution	Funding Restriction Percentage	Funding Restriction Reason	Funding Restriction has been Lifted
Fors Marsh Group LLC			

Institution	Institution Role(s)	Institution Project Title	Institution Project Tracking #	Prime Institution
Fors Marsh Group LLC	Implementing the Project			

Institution	Regulatory Coverage	IRB Review Status
Fors Marsh Group LLC	Conducting Exempt Human Research	

Institution	Registered IRB	IRB Registration Exp. Date	IRB Approval Status
Fors Marsh Group LLC			

Institution	IRB Approval Date	IRB Approval Exp. Date	Relying Institution IRB
Fors Marsh Group LLC			

Staff

Staff Member	SIQT Exp. Date	CITI Biomedical Exp. Date	CITI Social & Behavioral Exp. Date	CITI Good Clinical Practice Exp. Date	Staff Role	Email	Phone	Organization
Jasmine Kenney	11/26/2026		01/24/2025		Technical Monitor	hbu2@cdc.gov	404-639-0826	EDUCATION, CAMPAIGNS, AND IMPLEMENTATION TEAM

Data

DMP

Proposed Data Collection Start Date: 7/1/24

Proposed Data Collection End Date: 8/31/24

Proposed Public Access Level: Non-Public

Non-Public Details:

Reason For Not Releasing Data: Other - program evaluation

Public Access Justification: Data are for program evaluation and would not be useful to the public.

How Access Will Be Provided for Data:

Data files will be stored on contractor secure servers. The contractor will not share individual-level data beyond the immediate project team. Once data are collected and de-identified, the research team can share the final de-identified dataset as requested by CDC (e.g., providing de-identified feedback, transcripts or notes). All responses will be maintained separately from participant demographic responses and any responses to stimuli. Names will not be used in reporting, instead characteristics such as participant type, gender, and age will be used to describe feedback from participants in the report. During data collection activities (providing feedback on the digital platform), participants will only be identified by their first name, with no accompanying profile picture, to protect their privacy and to increase their comfort level with the discussion. Any PII that participants may provide in their responses will be scrubbed before reporting. None of the questions, prompts, or data elements in the activities will require participants to share information about themselves that is private or sensitive, although participants may share whatever they choose. All participants will be informed that all responses are voluntary, and they do not have to respond to any questions that they do not wish to answer.

The datasets for this project are unlikely to require long-term storage. The contractor's data retention policy differentiates raw, interim, and finalized datasets for storage and destruction policies, with the understanding that the Contractor will supervise the

Plans for Archival and Long Term Preservation:

authorized destruction of all raw and interim data and reports within three years from the end of the project. Before destroying any data, the Contractor will record what data is being deleted (i.e., project name and data elements associated), record what system the data is being deleted from, and, for electronic files, take a screenshot of the directory structure both before and after deletion.

Spatiality

Country	State/Province	County/Region
United States		

Dataset

Dataset Title	Dataset Description	Data Publisher /Owner	Public Access Level	Public Access Justification	External Access URL	Download URL	Type of Data Released	Collection Start Date	Collection End Date
Dataset yet to be added...									

Supporting Info

Current	CDC Staff Member and Role	Date Added	Description	Supporting Info Type	Supporting Info
	Zirger_Jeffrey (wtj5) ICRO Reviewer	03/15/2024	NOA 0920-0879 (2023)	Notice of Action	NOA 0920-0879_2023.pdf
	Thomas_Diakima (nvb7) Project Contact	03/05/2024	Updated file	Other	nvb7_0900f3eb823164c0_20240305_DTD.docx
Current	Thomas_Diakima (nvb7) Project Contact	02/23/2024	Evaluation Survey Questionnaire Instrument	Other-Evaluation Survey Questionnaire	DOCR - OD2A Partner Evaluation Survey Instrument . docx

Current	Thomas_Diakima (nvb7) Project Contact	02/23/2024	Evaluation plan	Other-Evaluation plan	DOCR - TB2A - Research Plan - OD2A Partner Campaign Evaluation.docx
---------	---	------------	-----------------	-----------------------	--



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention